DOP2013000118A - Compuesto bicíclico - Google Patents

Compuesto bicíclico

Info

Publication number
DOP2013000118A
DOP2013000118A DO2013000118A DO2013000118A DOP2013000118A DO P2013000118 A DOP2013000118 A DO P2013000118A DO 2013000118 A DO2013000118 A DO 2013000118A DO 2013000118 A DO2013000118 A DO 2013000118A DO P2013000118 A DOP2013000118 A DO P2013000118A
Authority
DO
Dominican Republic
Prior art keywords
bicyclic compound
present
compound
obesity
diabetes
Prior art date
Application number
DO2013000118A
Other languages
English (en)
Spanish (es)
Inventor
Ikuo Fujimori
Makoto Kamata
Tohru Yamashita
Hideki Hirose
Asato Kina
Masataka Murakami
Ryn Mizojiri
Kazuko Yonemori
Takuya Fujimoto
Zenichi Ikeda
Tsuco Yasuma
Original Assignee
Tekeda Pharmaceutical Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tekeda Pharmaceutical Company Ltd filed Critical Tekeda Pharmaceutical Company Ltd
Publication of DOP2013000118A publication Critical patent/DOP2013000118A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DO2013000118A 2010-11-30 2013-05-29 Compuesto bicíclico DOP2013000118A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010266097 2010-11-30
JP2011175330 2011-08-10

Publications (1)

Publication Number Publication Date
DOP2013000118A true DOP2013000118A (es) 2013-09-30

Family

ID=45418740

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000118A DOP2013000118A (es) 2010-11-30 2013-05-29 Compuesto bicíclico

Country Status (24)

Country Link
US (1) US8729102B2 (enExample)
EP (1) EP2649062B1 (enExample)
JP (1) JP5824517B2 (enExample)
KR (1) KR20140001965A (enExample)
CN (1) CN103347872B (enExample)
AR (1) AR084032A1 (enExample)
AU (1) AU2011337565A1 (enExample)
BR (1) BR112013013417A2 (enExample)
CA (1) CA2819400A1 (enExample)
CL (1) CL2013001520A1 (enExample)
CO (1) CO6751239A2 (enExample)
CR (1) CR20130281A (enExample)
DO (1) DOP2013000118A (enExample)
EA (1) EA201390794A1 (enExample)
EC (1) ECSP13012719A (enExample)
ES (1) ES2536319T3 (enExample)
MA (1) MA34713B1 (enExample)
MX (1) MX2013006113A (enExample)
PE (1) PE20140161A1 (enExample)
PH (1) PH12013501099A1 (enExample)
SG (1) SG190925A1 (enExample)
TW (1) TW201242951A (enExample)
UY (1) UY33756A (enExample)
WO (1) WO2012074126A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103025716B (zh) 2010-04-27 2014-12-24 武田药品工业株式会社 二环化合物衍生物及其作为acc抑制剂的用途
CA2853221A1 (en) 2011-10-24 2013-05-02 Tohru Yamashita Bicyclic compound
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
PL403149A1 (pl) * 2013-03-14 2014-09-15 Celon Pharma Spółka Akcyjna Nowe związki pochodne pirazolilobenzo[d]imidazolu
CA2911818A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
CA2911932A1 (en) * 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
MX2015015417A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
CN105358155A (zh) 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
BR112016004118A2 (pt) 2013-09-12 2017-10-17 Pfizer uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
EP3068788A1 (en) 2013-11-14 2016-09-21 Cadila Healthcare Limited Novel heterocyclic compounds
CR20170076A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
KR102586736B1 (ko) * 2014-08-29 2023-10-11 씨에이치디아이 파운데이션, 인코포레이티드 헌팅틴을 단백질 영상화하기 위한 프로브
JP2016079168A (ja) * 2014-10-17 2016-05-16 塩野義製薬株式会社 9員縮合環誘導体
CN104447725B (zh) * 2014-10-22 2018-02-02 浙江大学 一种手性含亚胺吡啶噁唑啉的化合物及其制备方法
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
BR112018006005A2 (pt) * 2015-09-29 2018-10-30 Oncotherapy Science Inc composto bicíclico e uso do mesmo para inibição de suv39h2
CN105601626A (zh) * 2015-11-04 2016-05-25 浙江大学 一种含2-取代噁唑啉衍生物的制备方法
TWI744256B (zh) 2015-11-06 2021-11-01 美商英塞特公司 作為PI3K-γ抑制劑之雜環化合物
TW201734003A (zh) 2016-01-05 2017-10-01 英塞特公司 作為PI3K-γ抑制劑之吡啶及嘧啶化合物
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
CN110753684A (zh) 2017-04-24 2020-02-04 特沙诺有限公司 尼拉帕利的制造方法
AU2018350980C1 (en) 2017-10-18 2024-12-12 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
AU2020408107B2 (en) 2019-12-20 2026-04-23 Nuevolution A/S Compounds active towards nuclear receptors
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
EP4434520A4 (en) 2021-11-19 2025-10-29 Shionogi & Co PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF HEART DISEASE OR SKELETAL MUSCLE DISEASE
AR129265A1 (es) 2022-05-12 2024-08-07 Syngenta Crop Protection Ag Compuestos de alcoxi-heteroaril-carboxamida o tioamida
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
EP4634152A1 (en) 2022-12-15 2025-10-22 Syngenta Crop Protection AG Novel bicyclic-carboxamide compounds useful as pesticides

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
ATE286395T1 (de) * 1997-04-30 2005-01-15 Lilly Co Eli Antithrombotische mittel
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
EP1542997B1 (en) * 2002-07-24 2012-02-29 Dermira (Canada), Inc. Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
EP1556032A1 (en) 2002-11-01 2005-07-27 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
CA2551610A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical COMPOUND OF PHENOXYALKANOIC ACID
TW200740435A (en) 2005-08-10 2007-11-01 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP1996567B1 (en) * 2006-02-15 2013-09-18 AbbVie Inc. Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
CL2007001873A1 (es) 2006-06-27 2008-01-04 Takeda Pharmaceutical Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
UA97257C2 (en) 2006-10-19 2012-01-25 Такеда Фармасьютикал Компани Лимитед Indole derivatives
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
MX2009008103A (es) 2007-02-09 2009-08-18 Takeda Pharmaceutical Compuestos anulares fusionados como agonistas parciales de prar-gamma.
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素5員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
US8927576B2 (en) * 2009-04-06 2015-01-06 PTC Therpeutics, Inc. HCV inhibitor and therapeutic agent combinations
CN103025716B (zh) 2010-04-27 2014-12-24 武田药品工业株式会社 二环化合物衍生物及其作为acc抑制剂的用途
WO2012108478A1 (ja) 2011-02-09 2012-08-16 武田薬品工業株式会社 単環化合物

Also Published As

Publication number Publication date
JP2013545718A (ja) 2013-12-26
ES2536319T3 (es) 2015-05-22
SG190925A1 (en) 2013-07-31
CN103347872B (zh) 2014-12-24
AR084032A1 (es) 2013-04-17
PE20140161A1 (es) 2014-02-19
US20120142714A1 (en) 2012-06-07
EP2649062B1 (en) 2015-04-08
PH12013501099A1 (en) 2013-07-08
WO2012074126A1 (en) 2012-06-07
CO6751239A2 (es) 2013-09-16
MX2013006113A (es) 2013-11-01
JP5824517B2 (ja) 2015-11-25
UY33756A (es) 2012-06-29
CL2013001520A1 (es) 2013-10-18
ECSP13012719A (es) 2013-12-31
US8729102B2 (en) 2014-05-20
EP2649062A1 (en) 2013-10-16
KR20140001965A (ko) 2014-01-07
CA2819400A1 (en) 2012-06-07
CR20130281A (es) 2013-10-07
AU2011337565A2 (en) 2013-07-11
CN103347872A (zh) 2013-10-09
EA201390794A1 (ru) 2013-11-29
AU2011337565A1 (en) 2013-07-11
WO2012074126A9 (en) 2013-06-06
TW201242951A (en) 2012-11-01
BR112013013417A2 (pt) 2019-09-24
MA34713B1 (fr) 2013-12-03

Similar Documents

Publication Publication Date Title
ECSP13012719A (es) Compuesto bicíclico
ECSP14013329A (es) Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas
UY35821A (es) Compuesto heterocíclico
ECSP15028917A (es) Compuesto heterocíclico
ECSP12012160A (es) Compuesto heterociclico
CR11688A (es) Compuesto heterociclico
CR20150217A (es) Inhibidores de histona demetilasas
CO2019012125A2 (es) Inhibidores ip6k
CR20110440A (es) Compuestos de piridazinona
CO6640253A2 (es) Derivados de compuesto biciclico y su uso como inhibidores de acc
CR20130024A (es) Compuestos heterocíclicos fusionados
DOP2016000253A (es) Nuevos compuestos
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
CO6321240A2 (es) Compuestos de anillo fusionados como activadores de glucocinasa
DOP2013000051A (es) Compuestos heterociclico y sus usos
CL2013000310A1 (es) Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor b1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparacion, util para el tratamiento agudo o profilactico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades.
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
CR20160227A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
CL2012001758A1 (es) Uso de compuestos derivados de 8-hidroxiquinolin-7-carboxamida y sus sales, para el tratamiento y/o prevencion de infecciones fungicas.
ECSP16024805A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
CR20160226A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
AR098670A1 (es) Inhibidor de sglt1
UY35165A (es) Método profiláctico o terapéutico para el síndrome de sjogren
UY35603A (es) Compuesto heterocíclico
UY32088A (es) Compuesto heterociclico